跳到正文
原文
BioPharma Dive· Delilah Alvarado·· 28 天前AI 评分61

FDA接受Biohaven罕见病药Vyglxia新申请,预计明年一季度裁决

Biohaven’s previously rejected rare disease drug to get fresh FDA review

AI 导读

Biohaven周四披露,其用于脊髓小脑性共济失调的新药Vyglxia(troriluzole)新一轮美国新药申请已被FDA接受,预计明年一季度作出裁决。FDA将召集顾问委员会讨论相关数据。该药此前因关键试验设计等问题遭FDA拒绝,欧洲申请也已撤回;此次申报附有新支持性分析。消息公布后Biohaven股价上涨约25%。

正文

An article from site logo

U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease medicine spurned by previous FDA leadership.

Published Oct. 22, 2026

Delilah Alvarado's headshot

A photo of Biohaven CEO Vlad Coric

Biohaven CEO Vlad Coric Courtesy of Biohaven Ltd.

A rare disease drug previously rejected by the Food and Drug Administration will get a second look, giving its developer, Biohaven, another shot at a regulatory clearance. 

The Connecticut-based drug developer revealed in a regulatory filing Thursday that its refreshed application for Vyglxia, a drug that treats a nerve-damaging disorder, has been accepted for a review by the agency. The FDA will convene a panel of experts to discuss the findings, and expects to issue a new verdict in the first quarter of next year, according to Biohaven.  

The announcement offers the chance for an important regulatory reversal for Biohaven, the second iteration of a migraine drug developer Pfizer acquired in 2022. This Biohaven “2.0” is led by the same management team as the original, but has been pursuing a pipeline of medicines for multiple different diseases.

The most advanced of those therapies is Vyglxia. Biohaven has been developing it for a group of rare genetic disorders collectively called spinocerebellar ataxia, through which progressive neuronal damage leads to problems with balance, coordination and speech. If approved, it could be the first marketed medicine for the condition. Some analysts have predicted north of $1 billion in annual sales. 

Yet Vyglxia has encountered roadblocks with multiple drug regulators. In Europe, the company withdrew an approval application after evaluators there questioned Biohaven’s supportive evidence. U.S. regulators were similarly skeptical. Despite findings suggesting Vyglxia might slow disease progression by as much as 70%, the FDA found the key experiment the company ran unconvincing in part because of its design. The regulator formally rejected the treatment last November.

Biohaven claimed to have been blindsided by the decision, which was one of many controversial rare disease drug rejections issued by former FDA leadership. It also turned to cost cuts afterwards.

Still, the company didn’t abandon Vyglxia, and resubmitted the application with "new positive supportive analyses,” according to Thursday’s regulatory filing.  

The new disclosure sent Biohaven shares up by about 25% and triggered a series of optimistic notes from Wall Street analysts. The scheduling of an advisory committee meeting “substantially increases the probability of approval,” wrote TD Cowen analyst Tyler Van Buren.  

Turnover at the agency’s highest ranks has also made analysts more bullish on Biohaven’s chances. The FDA has recently reversed multiple decisions issued by former leaders. It’s also expressed a desire to become more flexible in reviewing rare disease medicines, specifically.  

That shift in stance “opens a real possibility” that Vyglxia could get to market, added RBC Capital Markets analyst Leonid Timashev. He did caution, however, that Biohaven’s chances could depend “largely on how extensive those flexibility changes have been.”

来源:BioPharma Dive · biopharmadive.com